Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product (Consumables, Instruments), By Type (IVD, LDT), By Application (Breast Cancer, Lung Cancer), By End-use, By Test Type, And Segment Forecasts, 2024 - 2030

Cancer Diagnostics Market Size, Share & Trends Analysis Report By Product (Consumables, Instruments), By Type (IVD, LDT), By Application (Breast Cancer, Lung Cancer), By End-use, By Test Type, And Segment Forecasts, 2024 - 2030


Cancer Diagnostics Market Growth & Trends

The global cancer diagnostics market size is expected to reach USD 162.31 billion by 2030, as per the new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 6.16% from 2024 to 2030. Increasing number of programs to raise awareness about cancer by several organizations is a major factor accountable for increased demand for diagnostic products worldwide. Partnerships and collaborations undertaken by the National Cervical Cancer Coalition, WHO, CDC, the U.S. Preventive Services Task Force, & others for increasing cervical cancer screening are among the major factors expected to boost market growth during the forecast period.

Several countries have thus undertaken measures to increase screening for early diagnosis and help existing patients. For instance, Ayushman Bharat and the Prime Minister’s National Relief Fund was initiated by the Indian government for patients who require assistance during the treatment. Similarly, the Indian government’s Department of Biotechnology signed a contract with Cancer Research UK to conduct research for affordable approaches to diagnosis and treatment.

Liquid biopsy solutions are being increasingly adopted as MCED tests as they are easily accessible for clinical applications. In recent years, they have gained regulatory approval with comprehensive and multi-cancer diagnostic approaches. Breakthrough advancements in the field and ongoing studies for early detection are contributing to market growth. Moreover, technologies such as circulating tumor DNA, extracellular vesicles, and circulating tumor cells are paving the way for better cancer care. Versatile technologies can provide integrated solutions for maximizing the potential of liquid biopsy.

Advantage of using companion diagnostics is the overall reduction in time and costs incurred by pharmaceutical and diagnostic companies. The time required to develop and commercialize a novel molecule generally consists of 10 to 15 years. Co-development of diagnostics and drugs facilitates accelerated regulatory approval processes, which significantly reduces costs. . Since the FDA guidance draft for the development of an IVD companion diagnostic device with a therapeutic product was published in 2016, many manufacturers encourage the development of companion diagnostic assays in the field of oncology. This is anticipated to positively impact market growth during the forecast period.

Cancer Diagnostics Market Report Highlights
  • Based on product, the consumables segment held the largest share of 59.98% in 2023 and is anticipated to grow at the fastest growth rate over the forecast period
  • Based on type, in vitro diagnostics (IVD) segment dominated the in 2023 with a share of 52.75% due to the increasing adoption of IVD owing to the rise in testing amid COVID-19 pandemic.
  • The breast cancer application segment is expected to grow lucratively over the forecast period due to growth in initiatives to spread awareness across the population and increase in R&D activities.
  • Based on end-use, the laboratories segment dominated the market due to efficient outpatient services. The hospitals segment is forecasted grow at a significant rate over the coming years attributed to an increase in the admittance of patients in hospitals
  • The biopsy segment is anticipated to grow at a significant growth rate due to various benefits associated with the test, including early detection of the disease
  • North America dominated the global cancer diagnostics market in 2023, owing to rise in the number of approvals of new diagnostic tests
  • The Asia Pacific is expected to grow considerably in the future owing to due to the rising prevalence and the presence of key players
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Market Segmentation
1.1.1. Market Definitions
1.2. Objectives
1.2.1. Objective - 1
1.2.2. Objective - 2
1.2.3. Objective - 3
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Gvr’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information Or Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity Flow Analysis
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. List of Primary Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Product and Type Snapshot
2.3. Application and End-use Snapshot
2.4. Test Type Snapshot
2.5. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Segmentation and Scope
3.2. Market Lineage Outlook
3.2.1. Parent Market Outlook
3.2.2. Related/Ancillary Market Outlook
3.3. Market Dynamics
3.4. Market Drivers
3.4.1. Rising Prevalence of Cancer
3.4.2. Technological Advancements
3.4.3. Rising Initiatives Undertaken by Public and Private Organizations
3.4.4. Extensive R&D for the Development of Novel Testing Solutions
3.5. Market Restraint Analysis
3.5.1. High Cost of Diagnostic Imaging
3.5.2. Radiation Exposure Likely to Limit Usage of CT Scans
3.5.3. Rising Adoption of Refurbished Diagnostic Imaging Systems
3.6. Business Environment Analysis
3.6.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
3.6.2. Porter’s Five Forces Analysis
3.6.3. COVID-19 Impact Analysis
Chapter 4. Product Business Analysis
4.1. Cancer Diagnostics Market: Product Movement Analysis
4.2. Instruments
4.2.1. Instruments Market, 2018 - 2030 (USD Billion)
4.2.2. Pathology Based-Instruments
4.2.2.1. Slide Staining Systems
4.2.2.1.1. Slide Staining Systems Market, 2018 - 2030 (USD Billion)
4.2.2.2. Tissue Processing Systems
4.2.2.2.1. Tissue Processing Systems Market, 2018 - 2030 (USD Billion)
4.2.2.3. Cell Processors
4.2.2.3.1. Cell Processors Systems Market, 2018 - 2030 (USD Billion)
4.2.2.4. PCR Instruments
4.2.2.4.1. PCR Instruments Market, 2018 - 2030 (USD Billion)
4.2.2.5. NGS Instruments
4.2.2.5.1. NGS Instruments Market, 2018 - 2030 (USD Billion)
4.2.2.6. Microarrays
4.2.2.6.1. Microarrays Market, 2018 - 2030 (USD Billion)
4.2.2.7. Other Pathology-based Instruments
4.2.2.7.1. Other Pathology-based Instruments Market, 2018 - 2030 (USD Billion)
4.2.3. Imaging Instruments
4.2.4. Others
4.3. Consumables
4.3.1. Consumables Market, 2018 - 2030 (USD Billion)
4.4. Services
4.4.1. Services Market, 2018 - 2030 (USD Billion)
Chapter 5. Type Business Analysis
5.1. Cancer Diagnostics Market: Type Movement Analysis
5.2. IVD
5.2.1. IVD Market, 2018 - 2030 (USD Billion)
5.2.2. IVD Market, By Type 2018 - 2030 (USD Billion)
5.2.2.1. Diagnosis
5.2.2.1.1. Diagnosis Market, 2018 - 2030 (USD Billion)
5.2.2.2. Early Detection
5.2.2.2.1. Early Detection Market, 2018 - 2030 (USD Billion)
5.2.2.3. Therapy Selection
5.2.2.3.1. Therapy Selection Market, 2018 - 2030 (USD Billion)
5.2.2.4. Monitoring
5.2.2.4.1. Monitoring Market, 2018 - 2030 (USD Billion)
5.2.3. IVD Market, By Technology 2018 - 2030 (USD Billion)
5.2.3.1. Polymerase Chain Reaction (PCR)
5.2.3.1.1. Polymerase Chain Reaction (PCR) Market, 2018 - 2030 (USD Billion)
5.2.3.2. In Situ Hybridization (ISH)
5.2.3.2.1. In Situ Hybridization (ISH) Market, 2018 - 2030 (USD Billion)
5.2.3.3. Immunohistochemistry (IHC)
5.2.3.3.1. Immunohistochemistry (IHC) Market, 2018 - 2030 (USD Billion)
5.2.3.4. Next-generation Sequencing (NGS)
5.2.3.4.1. Next-generation Sequencing (NGS) Market, 2018 - 2030 (USD Billion)
5.2.3.5. Microarrays
5.2.3.5.1. Microarrays Market, 2018 - 2030 (USD Billion)
5.2.3.6. Flow Cytometry
5.2.3.6.1. Flow Cytometry Market, 2018 - 2030 (USD Billion)
5.2.3.7. Immunoassays
5.2.3.7.1. Immunoassays Market, 2018 - 2030 (USD Billion)
5.2.3.8. Other IVD Testing Technologies
5.2.3.8.1. Other IVD Testing Technologies Market, 2018 - 2030 (USD Billion)
5.3. LDT
5.3.1. LDT Market, 2018 - 2030 (USD Billion)
5.4. Imaging
5.4.1. Imaging Market, 2018 - 2030 (USD Billion)
5.4.2. Magnetic Resonance Imaging (MRI)
5.4.2.1. Magnetic Resonance Imaging (MRI) Market, 2018 - 2030 (USD Billion)
5.4.3. Computed Tomography (CT)
5.4.3.1. Computed Tomography (CT) Market, 2018 - 2030 (USD Billion)
5.4.4. Positron Emission Tomography (PET)
5.4.4.1. Positron Emission Tomography (PET) Market, 2018 - 2030 (USD Billion)
5.4.5. Mammography
5.4.5.1. Mammography Market, 2018 - 2030 (USD Billion)
5.4.6. Ultrasound
5.4.6.1. Ultrasound Market, 2018 - 2030 (USD Billion)
5.4.7. Others
5.4.7.1. Others Market, 2018 - 2030 (USD Billion)
Chapter 6. Application Business Analysis
6.1. Cancer Diagnostics Market: Application Movement Analysis
6.2. Breast Cancer
6.2.1. Breast Cancer Market, 2018 - 2030 (USD Billion)
6.3. Colorectal Cancer
6.3.1. Colorectal Cancer Market, 2018 - 2030 (USD Billion)
6.4. Cervical Cancer
6.4.1. Cervical Cancer Market, 2018 - 2030 (USD Billion)
6.5. Lung Cancer
6.5.1. Lung Cancer Market, 2018 - 2030 (USD Billion)
6.6. Prostate Cancer
6.6.1. Prostate Cancer Market, 2018 - 2030 (USD Billion)
6.7. Skin Cancer
6.7.1. Skin Cancer Market, 2018 - 2030 (USD Billion)
6.8. Blood Cancer
6.8.1. Blood Cancer Market, 2018 - 2030 (USD Billion)
6.9. Kidney Cancer
6.9.1. Kidney Cancer Market, 2018 - 2030 (USD Billion)
6.10. Liver Cancer
6.10.1. Liver Cancer Market, 2018 - 2030 (USD Billion)
6.11. Pancreatic Cancer
6.11.1. Pancreatic Cancer Market, 2018 - 2030 (USD Billion)
6.12. Ovarian Cancer
6.12.1. Ovarian Cancer Market, 2018 - 2030 (USD Billion)
6.13. Others
6.13.1. Others Market, 2018 - 2030 (USD Billion)
Chapter 7. End-Use Business Analysis
7.1. Cancer Diagnostics Market: End-Use Movement Analysis
7.2. Hospitals
7.2.1. Hospitals Market, 2018 - 2030 (USD Billion)
7.3. Laboratories
7.3.1. Laboratories Market, 2018 - 2030 (USD Billion)
7.4. Others
7.4.1. Others Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
Chapter 8. Test Type Business Analysis
8.1. Cancer Diagnostics Market: Test Type Movement Analysis
8.2. Biopsy
8.2.1. Biopsy Market, 2018 - 2030 (USD Billion)
8.2.2. Fine-needle Aspiration
8.2.2.1. Fine-needle Aspiration Market, 2018 - 2030 (USD Billion)
8.2.3. Core Biopsy
8.2.3.1. Core Biopsy Market, 2018 - 2030 (USD Billion)
8.2.4. Surgical Biopsy
8.2.4.1. Surgical Biopsy Market, 2018 - 2030 (USD Billion)
8.2.5. Skin Biopsy /Punch Biopsy
8.2.5.1. Skin Biopsy /Punch Biopsy Market, 2018 - 2030 (USD Billion)
8.2.6. Others
8.2.6.1. Others Market, 2018 - 2030 (USD Billion)
8.3. Others
8.3.1. Others Cancer Diagnostics Market, 2018 - 2030 (USD Billion)
Chapter 9. Product Business Analysis
9.1. Cancer Diagnostics Market: Product Movement Analysis
9.2. Instruments
9.2.1. Instruments Market, 2018 - 2030 (USD Billion)
9.3. Consumables Kits and Reagents
9.3.1. Consumables Kits and Reagents Market, 2018 - 2030 (USD Billion)
9.4. Software and Services
9.4.1. Software and Services Market, 2018 - 2030 (USD Billion)
Chapter 10. Regional Business Analysis
10.1. Cancer Diagnostics Market Share By Region, 2023 & 2030
10.2. North America
10.2.1. North America Cancer diagnostics market, 2018 - 2030 (USD Billion)
10.2.2. U.S.
10.2.2.1. Key Country Dynamics
10.2.2.2. Target Disease Prevalence
10.2.2.3. Competitive Scenario
10.2.2.4. Regulatory Framework
10.2.2.5. Reimbursement Scenario
10.2.2.6. U.S. Cancer diagnostics market, 2018 - 2030 (USD BILLION)
10.2.3. Canada
10.2.3.1. Key Country Dynamics
10.2.3.2. Target Disease Prevalence
10.2.3.3. Competitive Scenario
10.2.3.4. Regulatory Framework
10.2.3.5. Reimbursement Scenario
10.2.3.6. Canada Cancer diagnostics market, 2018 - 2030 (USD Billion)
10.3. Europe
10.3.1. Europe Cancer diagnostics market, 2018 - 2030 (USD Billion)
10.3.2. Germany
10.3.2.1. Key Country Dynamics
10.3.2.2. Target Disease Prevalence
10.3.2.3. Competitive Scenario
10.3.2.4. Regulatory Framework
10.3.2.5. Reimbursement Scenario
10.3.2.6. Germany Cancer diagnostics market, 2018 - 2030 (USD Billion)
10.3.3. UK
10.3.3.1. Key Country Dynamics
10.3.3.2. Target Disease Prevalence
10.3.3.3. Competitive Scenario
10.3.3.4. Regulatory Framework
10.3.3.5. Reimbursement Scenario
10.3.3.6. UK Cancer diagnostics market, 2018 - 2030 (USD Billion)
10.3.4. France
10.3.4.1. Key Country Dynamics
10.3.4.2. Target Disease Prevalence
10.3.4.3. Competitive Scenario
10.3.4.4. Regulatory Framework
10.3.4.5. Reimbursement Scenario
10.3.4.6. France Cancer diagnostics market, 2018 - 2030 (USD Billion)
10.3.5. Italy
10.3.5.1. Key Country Dynamics
10.3.5.2. Target Disease Prevalence
10.3.5.3. Competitive Scenario
10.3.5.4. Regulatory Framework
10.3.5.5. Reimbursement Scenario
10.3.5.6. Italy Cancer diagnostics market, 2018 - 2030 (USD Billion)
10.3.6. Spain
10.3.6.1. Key Country Dynamics
10.3.6.2. Target Disease Prevalence
10.3.6.3. Competitive Scenario
10.3.6.4. Regulatory Framework
10.3.6.5. Reimbursement Scenario
10.3.6.6. Spain Cancer diagnostics market, 2018 - 2030 (USD Billion)
10.3.7. Denmark
10.3.7.1. Key Country Dynamics
10.3.7.2. Target Disease Prevalence
10.3.7.3. Competitive Scenario
10.3.7.4. Regulatory Framework
10.3.7.5. Reimbursement Scenario
10.3.7.6. Denmark Cancer diagnostics market, 2018 - 2030 (USD Billion)
10.3.8. Sweden
10.3.8.1. Key Country Dynamics
10.3.8.2. Target Disease Prevalence
10.3.8.3. Competitive Scenario
10.3.8.4. Regulatory Framework
10.3.8.5. Reimbursement Scenario
10.3.8.6. Sweden Cancer diagnostics market, 2018 - 2030 (USD Billion)
10.3.9. Norway
10.3.9.1. Key Country Dynamics
10.3.9.2. Target Disease Prevalence
10.3.9.3. Competitive Scenario
10.3.9.4. Regulatory Framework
10.3.9.5. Reimbursement Scenario
10.3.9.6. Norway Cancer diagnostics market, 2018 - 2030 (USD Billion)
10.4. Asia Pacific
10.4.1. Asia Pacific Cancer diagnostics market, 2018 - 2030 (USD Billion)
10.4.2. Japan
10.4.2.1. Key Country Dynamics
10.4.2.2. Target Disease Prevalence
10.4.2.3. Competitive Scenario
10.4.2.4. Regulatory Framework
10.4.2.5. Reimbursement Scenario
10.4.2.6. Japan Cancer diagnostics market, 2018 - 2030 (USD Billion)
10.4.3. China
10.4.3.1. Key Country Dynamics
10.4.3.2. Target Disease Prevalence
10.4.3.3. Competitive Scenario
10.4.3.4. Regulatory Framework
10.4.3.5. Reimbursement Scenario
10.4.3.6. China Cancer diagnostics market, 2018 - 2030 (USD Billion)
10.4.4. India
10.4.4.1. Key Country Dynamics
10.4.4.2. Target Disease Prevalence
10.4.4.3. Competitive Scenario
10.4.4.4. Regulatory Framework
10.4.4.5. Reimbursement Scenario
10.4.4.6. India Cancer diagnostics market, 2018 - 2030 (USD Billion)
10.4.5. South Korea
10.4.5.1. Key Country Dynamics
10.4.5.2. Target Disease Prevalence
10.4.5.3. Competitive Scenario
10.4.5.4. Regulatory Framework
10.4.5.5. Reimbursement Scenario
10.4.5.6. South Korea Cancer diagnostics market, 2018 - 2030 (USD Billion)
10.4.6. Australia
10.4.6.1. Key Country Dynamics
10.4.6.2. Target Disease Prevalence
10.4.6.3. Competitive Scenario
10.4.6.4. Regulatory Framework
10.4.6.5. Reimbursement Scenario
10.4.6.6. Australia Cancer diagnostics market, 2018 - 2030 (USD Billion)
10.4.7. Thailand
10.4.7.1. Key Country Dynamics
10.4.7.2. Target Disease Prevalence
10.4.7.3. Competitive Scenario
10.4.7.4. Regulatory Framework
10.4.7.5. Reimbursement Scenario
10.4.7.6. Thailand Cancer diagnostics market, 2018 - 2030 (USD Billion)
10.5. Latin America
10.5.1. Latin America Cancer diagnostics market, 2018 - 2030 (USD Billion)
10.5.2. Brazil
10.5.2.1. Key Country Dynamics
10.5.2.2. Target Disease Prevalence
10.5.2.3. Competitive Scenario
10.5.2.4. Regulatory Framework
10.5.2.5. Reimbursement Scenario
10.5.2.6. Brazil Cancer diagnostics market, 2018 - 2030 (USD Billion)
10.5.3. Mexico
10.5.3.1. Key Country Dynamics
10.5.3.2. Target Disease Prevalence
10.5.3.3. Competitive Scenario
10.5.3.4. Regulatory Framework
10.5.3.5. Reimbursement Scenario
10.5.3.6. Mexico Cancer diagnostics market, 2018 - 2030 (USD Billion)
10.5.4. Argentina
10.5.4.1. Key Country Dynamics
10.5.4.2. Target Disease Prevalence
10.5.4.3. Competitive Scenario
10.5.4.4. Regulatory Framework
10.5.4.5. Reimbursement Scenario
10.5.4.6. Argentina Cancer diagnostics market, 2018 - 2030 (USD Billion)
10.6. MEA
10.6.1. MEA Cancer diagnostics market, 2018 - 2030 (USD Billion)
10.6.2. South Africa
10.6.2.1. Key Country Dynamics
10.6.2.2. Target Disease Prevalence
10.6.2.3. Competitive Scenario
10.6.2.4. Regulatory Framework
10.6.2.5. Reimbursement Scenario
10.6.2.6. South Africa Cancer diagnostics market, 2018 - 2030 (USD Billion)
10.6.3. Saudi Arabia
10.6.3.1. Key Country Dynamics
10.6.3.2. Target Disease Prevalence
10.6.3.3. Competitive Scenario
10.6.3.4. Regulatory Framework
10.6.3.5. Reimbursement Scenario
10.6.3.6. Saudi Arabia Cancer diagnostics market, 2018 - 2030 (USD Billion)
10.6.4. UAE
10.6.4.1. Key Country Dynamics
10.6.4.2. Target Disease Prevalence
10.6.4.3. Competitive Scenario
10.6.4.4. Regulatory Framework
10.6.4.5. Reimbursement Scenario
10.6.4.6. UAE Cancer diagnostics market, 2018 - 2030 (USD Billion)
10.6.5. Kuwait
10.6.5.1. Key Country Dynamics
10.6.5.2. Target Disease Prevalence
10.6.5.3. Competitive Scenario
10.6.5.4. Regulatory Framework
10.6.5.5. Reimbursement Scenario
10.6.5.6. Kuwait Cancer diagnostics market, 2018 - 2030 (USD Billion)
Chapter 11. Competitive Landscape
11.1. Participant’s overview
11.2. Financial performance
11.3. Participant categorization
11.3.1. Market Leaders
11.3.2. Cancer Diagnostics Market Share Analysis, 2023
11.3.3. Company Profiles
11.3.3.1. ABBOTT
11.3.3.1.1. Company Overview
11.3.3.1.2. Financial Performance
11.3.3.1.3. Product Benchmarking
11.3.3.1.4. Strategic Initiatives
11.3.3.2. GE HEALTHCARE
11.3.3.2.1. Company Overview
11.3.3.2.2. Financial Performance
11.3.3.2.3. Product Benchmarking
11.3.3.2.4. Strategic Initiatives
11.3.3.3. F. HOFFMANN-LA ROCHE LTD.
11.3.3.3.1. Company Overview
11.3.3.3.2. Financial Performance
11.3.3.3.3. Product Benchmarking
11.3.3.3.4. Strategic Initiatives
11.3.3.4. QIAGEN
11.3.3.4.1. Company Overview
11.3.3.4.2. Financial Performance
11.3.3.4.3. Product Benchmarking
11.3.3.4.4. Strategic Initiatives
11.3.3.5. BD
11.3.3.5.1. Company Overview
11.3.3.5.2. Financial Performance
11.3.3.5.3. Product Benchmarking
11.3.3.5.4. Strategic Initiatives
11.3.3.6. SIEMENS HEALTHCARE GMBH
11.3.3.6.1. Company Overview
11.3.3.6.2. Financial Performance
11.3.3.6.3. Product Benchmarking
11.3.3.6.4. Strategic Initiatives
11.3.3.7. THERMO FISHER SCIENTIFIC, INC.
11.3.3.7.1. Company Overview
11.3.3.7.2. Financial Performance
11.3.3.7.3. Product Benchmarking
11.3.3.7.4. Strategic Initiatives
11.3.3.8. HOLOGIC, INC.
11.3.3.8.1. Company Overview
11.3.3.8.2. Financial Performance
11.3.3.8.3. Product Benchmarking
11.3.3.8.4. Strategic Initiatives
11.3.3.9. KONINKLIJKE PHILIPS N.V. (PHILIPS)
11.3.3.9.1. Company Overview
11.3.3.9.2. Financial Performance
11.3.3.9.3. Product Benchmarking
11.3.3.9.4. Strategic Initiatives
11.3.3.10. ILLUMINA, INC.
11.3.3.10.1. Company Overview
11.3.3.10.2. Financial Performance
11.3.3.10.3. Product Benchmarking
11.3.3.10.4. Strategic Initiatives
11.3.4. Strategy Mapping
11.3.4.1. Expansion
11.3.4.2. Acquisition
11.3.4.3. Collaborations
11.3.4.4. Disease Type/Drug Class Launch
11.3.4.5. Partnerships
11.3.4.6. Others

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings